LEXINGTON, KY / ACCESS Newswire / April 6, 2026 / NX Development Corp (NXDC) is pleased to announce that after successfully completing the data analysis of our MEN-301 Study of the use of Gleolan ® ...
Lexington, KY, Jan. 12, 2021 (GLOBE NEWSWIRE) -- NX Development Corp. (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced FDA orphan-drug designation for Gleolan ...
“This marks the first submission of supplemental data to the FDA since our original approval for high-grade glioma in 2017, and the culmination of a great amount of hard work by our dedicated NXDC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results